contraindications for glp-1 agonists Consensus Recommendations on RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force Semaglutide Contraindications & Medical Screening

How do we complete these procedures with patients wide awake

Treatment with exenatide has been shown to decrease food intake and attenuate food-related neural responses in key regions such as the insula, amygdala, putamen, and orbitofrontal cortex (van Bloemendaal et al., 2014)

Neurosurgery 94:648656, 2024 Although venous sinus stenting (VSS) improves cerebrospinal uid reabsorption and decreases intracranial pressure in patients with idiopathic intracranial hypertension (IIH), the underlying pathophysiology of IIH is not well understood

J Biol Chem 265:1291612926 Richards EM, Rosenthal RE, Kristian T, Fiskum G (2006) Postischemic hyperoxia reduces hippocampal pyruvate dehydrogenase activity

The Three Generations of Incretin Peptide Research The progression from single to dual to triple agonist peptides represents a research trajectory that has played out in roughly ten years: Generation 1 Single GLP-1 Agonists (Semaglutide, Liraglutide, Exenatide) The first incretin peptides to reach broad clinical research were GLP-1 receptor agonists